Canada legalized cannabis on October 17, 2018. The market is expected to reach $20.6 billion by 2024 and could grow exponentially if the U.S grasps the opportunity to legalize as well even just for medicinal purposes. But legalization has brought with it new challenges for consumers who would like an alternative consumption method that does not involve smoke or vaporizing their bud in a joint or bowl..
The purpose of the invention, which has been licensed to a Vancouver business, is to commercialize items in the form of a nasal spray using technology that turns liquid solution to a gel.
The University of Queensland (U.Q.) in Australia and PreveCeutical Medicinal Inc. in Canada have joined together to create a liquid that changes to a gel, which is being hailed as a “revolutionary transformation” in how patients will consume medical cannabis.
The Sol-Gel technology was developed by a team of researchers from the University of Queensland’s School of Pharmacy, lead by Dr. Harendra Parekh, who said that when a liquid solution comes into touch with “interior membranes of the human body, such as the nose,” it transforms into a gel.
PreveCeutical, based in Vancouver, will have the opportunity to see firsthand what the technology can achieve. PreveCeutical, together with its partners, investigates and develops solutions that provide customers alternatives for preventative and curative therapy.
According to a statement from the university, PreveCeutical has signed an agreement with Uniquest, the university’s commercialization firm, for the “rights to utilise the Sol-Gel technology for the precise delivery of cannabinoids to all areas and membranes of the human body.” According to the university, the sale includes a license to the patent application.
Membranes are “think sheets of tissue that wrap the body, line body cavities, and cover organs inside the spaces of hollow organs,” according to the National Cancer Institute. Epithelial, serous, connective tissue, synovial, meninges, and muscous are some of the many kinds.
When it comes to Sol-Gel technology, the final alternative seems to be of the most urgent interest.
“We’ve been working with U.Q. via UniQuest on the cannabis Sol-Gel delivery system since 2017, with an emphasis on nasal administration,” PreveCeutical chairman and CEO Stephen Van Deventer said in the U.Q. announcement.
“Now that we have this license agreement in place, we can work with partners to commercialize cannabinoid Sol-Gel formulation products in the form of a nasal spray,” Van Deventer says.
In a statement, UniQuest CEO Dr. Dean Moss states, “This arrangement is a tremendous testimonial to the strength and desire of U.Q. academics to engage with business and work together to make impact via the development of possible new medicines.”
According to Van Deventer, his business plans to investigate additional product forms for delivering cannabinoids using the technology, such as via the skin.
Researchers looked at using CBD to treat rats with chronic and breakthrough pain in a study published a decade ago. Their findings suggested that CBD might be given effectively through intranasal and transdermal methods.
“Many exceptional formulations containing cannabinoids are already developing and are being validated in various clinical studies,” according to the authors of an Italian research published this year on pain therapy. They did warn, however, that “more study is needed to examine the ideal route and composition of cannabinoids in pain treatment,” and that “additional research is needed to investigate the optimal route and composition of cannabinoids in pain treatment.”
According to a 2018 study, “the low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration, and transmucosal adsorption,” “the low oral bioavailability of cannabinoids has led to feasible methods of administration, such as the transdermal route, intranasal administration, and transmucosal adsorption, being proposed.”
“Cannabinoids are viewed as potential candidates for improved nanosized drug delivery systems, which may be administered through a variety of channels,” the researchers write.